Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | July 09, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date July 09, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,800 |
Reported balance
After 2026-07-09 transaction · row 1
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 21,800 · Balance 21,800 F1: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 23:35 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0002137444-26-000007 · form4-07102026_110702.xml · nonDerivative · entry 1 Meehan Viola Mong · CIK 0002137444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,800 F1 · shares: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date. Read SEC document |
| May 30, 2026 Filed Jun 3, 2026 00:42 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (Right to Buy) · Derivative | 1,626 | $0.00 Strike: $21.90 | $0.00 |
DisclosureSEC source: 0002137444-26-000005 · form4-06032026_120657.xml · derivative · entry 1 Meehan Viola Mong · CIK 0002137444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626 Underlying: Common Stock · 1,626 shares Expires 2036-05-29 F1 · derivative.exercise_date: The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.